Skip to main content
. 2014 Jan 2;124(2):553–563. doi: 10.1172/JCI69804

Figure 3. EPO promotes progression of orthotopic C3-Tag and MMTV-Neu tumors.

Figure 3

(A) 1 × 105 luciferase-expressing C3-Tag cells were implanted into the mammary fat pads of FVB/N mice. The mice were randomized to receive PBS or EPO (500 IU/kg BIW). Representative Xenogen images of mice on day 1 and day 21 after injection. (B) Living Image software (Caliper Life Sciences) was used to quantify luciferase activity of orthotopic C3-Tag tumors. Mean photons/s/cm2 is graphed with error bars representing SEM. *P ≤ 0.05 on day 21. (C) Tumor volume of orthotopically implanted NT2 cells as measured by calipers. ***P ≤ 0.001. (D and E) Kaplan-Meier curves of percentage of C3-Tag tail vein–injected mice alive in the indicated treatment groups.